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Abstract
Background:  It is important to develop innovative therapies for advanced stage cancers in
addition to the conventional therapies including chemotherapy, radiation and surgery. Antigen-
specific immunotherapy has emerged as a novel alternate therapy for advanced stage cancers,
which may be employed in conjunction with conventional therapies.
Methods: In the current study, we tested the effect of treatment with the chemotherapeutic
agent, apigenin in combination with DNA vaccines encoding the HPV-16 E7 antigen linked to heat
shock protein 70 (HSP70) in the control of the E7-expressing tumor, TC-1.
Results:  We observed that treatment with apigenin rendered the TC-1 tumor cells more
susceptible to lysis by E7-specific cytotoxic CD8+ T cells. Furthermore, treatment of TC-1 tumor
cells with apigenin was found to enhance apoptotic tumor cell death in vitro in a dose-dependant
manner. We showed that TC-1 tumor-bearing mice treated with apigenin combined with E7-
HSP70 DNA generate highest frequency of primary and memory E7-specific CD8+ T cells, leading
to potent therapeutic anti-tumor effects against E7-expressing tumors.
Conclusion: Thus, apigenin represents a promising chemotherapeutic agent, which may be used
in combination with immunotherapy for the treatment of advanced stage cancers. The clinical
implications of the current strategy are discussed.
Background
Advanced stage cancers are difficult to control using con-
ventional therapies such as chemotherapy, radiation and/
or surgery. Thus, the development of innovative therapies
for advanced stage cancers is urgently needed. Antigen-
specific immunotherapy has the potency to eradicate sys-
temic tumors at multiple sites in the body, as well as the
specificity to discriminate between malignant and normal
cells. Thus, immunotherapy, such as DNA vaccination
provides a promising alternate approach for advanced
stage cancers, which may be employed in conjunction
with conventional therapies.
DNA vaccination has the advantages of purity, simplicity
of preparation, and stability. In addition, DNA-based vac-
cines can be prepared inexpensively and rapidly on a large
scale (for review, see [1,2]). However, due to the low
immunogenicity of DNA vaccines, strategies need to be
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developed to enhance DNA vaccine potency. Intradermal
administration of DNA vaccines via gene gun represents
an efficient way to deliver DNA vaccines into professional
APCs in vivo. In addition, several strategies have been
developed to enhance the potency of DNA vaccines by
modification of the properties of antigen-presenting cells
(APCs) (for review see [3-5]).
We have previously developed several intracellular target-
ing strategies to improve DNA vaccine potency by linkage
of antigen to proteins that target the antigen for proteaso-
mal degradation or entry into the endoplasmic reticulum
(ER), thus facilitating MHC class I presentation of linked
antigen in DCs. Vaccination with a fusion DNA construct
encoding E7 antigen linked to Mycobacterium tuberculosis
heat shock protein 70 (HSP70) (E7-HSP70) was shown to
enhance E7-specific CD8+ T-cell-mediated immune
responses and protect mice against E7-expressing TC-1
tumor growth [6]. This strategy is currently being trans-
lated to phase I/II clinical trials in patients with HPV-16
associated CIN lesions using the GMP grade E7-HSP70
DNA vaccine (pNGVL4a-Sig/E7(detox)/HSP70), which
has been tested in human vaccine trials [7]. In addition,
the same DNA vaccine has been used in HPV16+ patients
with advanced head and neck squamous cell carcinoma
(Dr. Maura Gillison, personal communication). Thus, the
current DNA vaccine has significant potential for clinical
translation for the treatment of HPV-associated malignan-
cies.
Another innovative approach for the control of cancer is
the employment of immunomodulatory chemotherapeu-
tic agents such as flavonoids. Flavonoids, such as epigallo-
catechin gallate (EGCG)) have been shown to have
positive immune modulating effects via mechanisms of
antioxidant, antiinflammatory, and anti-cyclooxygenase
activities [8,9]. Apigenin is of particular interest as an anti-
tumor agent since it exhibits lower intrinsic toxicity and is
not mutagenic as compared to other structurally related
flavonoids [10]. Furthermore, apigenin has been shown
to demonstrate antitumor effects in several tumor cell
lines, including those derived from prostate, pancreatic
and breast cancer [11-13]. Thus, apigenin represents a
promising chemotherapeutic agent for cancer therapy.
In the current study, we aim to test the combination of
apigenin treatment with E7-HSP70 DNA vaccination in
the control of the E7-expressing tumor, TC-1. We
observed that treatment with apigenin rendered the TC-1
tumor cells more susceptible to lysis by E7-specific CTLs.
Furthermore, treatment of TC-1 tumor cells with apigenin
was found to enhance apoptotic tumor cell death in vitro
in a dose-dependant manner. We showed that TC-1
tumor-bearing mice treated with apigenin combined with
E7-HSP70 DNA generate highest frequency of primary
and memory E7-specific CD8+ T cells, leading to potent
therapeutic anti-tumor effects against E7-expressing
tumors. The clinical implications of the current strategy
are discussed.
Materials and methods
Animals and Chemicals
Female C57BL/6 mice (H-2Kb and I-Ab), 5 to 6 weeks of
age, were purchased from National Cancer Institute (Fre-
derick, Maryland, USA) and kept in the oncology animal
facility of the Johns Hopkins Hospital (Baltimore, Mary-
land, USA). Animals were used in compliance with insti-
tutional animal health care regulations, and all animal
experimental procedures were approved by the Johns
Hopkins Institutional Animal Care and Use Committee.
Apigenin was purchased from Sigma-Aldrich (St. Louis,
Missouri, USA).
Murine Tumor Cell Line
The production and maintenance of TC-1 cells [14] and
E7-specific T cells [15] have been described previously.
Luciferase-expressing TC-1 cells (TC-1-luc) were generated
by transducing TC-1 cells with retrovirus containing luci-
ferase pLuci-thy1.1 and flow cytometry sorting following
the protocol described previously. Briefly, In order to gen-
erate a retrovirus containing luciferase, a pLucithy1.1 con-
struct expressing both luciferase and thy1.1 was made.
Firefly luciferase was amplified by PCR from pGL3-basic
(Promega) using the 5' primer CGGAGATCTATGGAA-
GACGCCAAAAAC and the 3' primer CGGGTTAACT-
TACGGCGATCTTTCC. The amplified luciferase cDNA
was inserted into the BglII and HpaI sites of the bicistronic
vector pMIG-thy1.1. Both luciferase and thy1.1 cDNA are
under the control of a single promoter element and sepa-
rated by an internal ribosomal entry site (IRES). The
pLuci-thy1.1 was transfected into Phoenix packaging cell
line and the virion-containing supernatant was collected
48 h after transfection. The supernatant was immediately
treated using a 0.45-mm cellulose acetate syringe filter
(Nalgene, Rochester, New York, USA) and used to infect
TC-1 in the presence of 8 mg/ml Polybrene (Sigma, St
Louis, Missouri, USA). TC-1-luc cells were sorted using
preparative flow cytometry of stained cells with thy1.1
antibody (BD, Franklin Lakes, New Jersey, USA). Both TC-
1 cell line and TC-1-luc cell line were maintained in RPMI
1640, supplemented with 10% (v/v) fetal bovine serum,
50 U/ml penicillin/streptomycin, 2 mM L-glutamine, 1
mM sodium pyruvate, 2 mM nonessential amino acids,
and 0.4 mg/ml G418 at 37°C with 5% CO2. On the day
of tumor challenge, TC-1 cells were harvested by trypsini-
zation, washed twice with 1× Hanks buffered salt solu-
tion, and finally resuspended in 1× Hanks buffered salt
solution to the designated concentration.Journal of Biomedical Science 2009, 16:49 http://www.jbiomedsci.com/content/16/1/49
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In Vitro Cytotoxicity Assay
Luciferase-expressing TC-1 cells [16] in medium were
seeded into a 24-well round-bottom plate (1 × 105 cells/
well). Twenty-four hours later, apigenin alone or in com-
bination with E7-specific T cells were added into each
well. Apigenin was dissolved in dimethyl sulfoxide
(DMSO) and mixed with fresh medium to achieve the
desired concentration of 0.2%. This concentration of
DMSO did not alter cell growth [17]. Cells treated with
solvent DMSO (0.1%) alone were used as controls. E7-
specific cytotoxic T lymphocytes from the spleens of
tumor bearing mice immunized with the DNA vaccine
served as effector cells and were added in the amount of 1
× 106 cells/well. TC-1 cells expressing luciferase were used
as target cells. After incubation, D-luciferin (potassium
salt; Xenogen Corp.) was added to each well at 150 g/ml
in media 5 min before imaging. Bioluminescence imaging
was taken at baseline, 24, 48, and 72 hours using the IVIS
Imaging System Series 200 (Xenogen, Cranbury, New Jer-
sey, USA). An integration time of 10 s was used for lumi-
nescence image acquisition. CTL-mediated killing was
assessed using bioluminescence-imaging systems quanti-
fying the decrease of luminescence from baseline.
Characterization of apoptotic cell death
The in vitro apoptotic effects of apigenin on TC-1 cells
were evaluated using two-colored fluorescence using a
phycoerythrin conjugated-Annexin V and 7-AAD apopto-
sis kit (BD PharMingen, San Diego, CA) following the
manufacturer's instructions. Briefly, TC-1 cells were co-
incubated with the indicated concentrations of apigenin,
and DMSO (0.1% v/v) was used as negative controls. At 6
and 48 hr post-incubation, TC-1 cells were harvested and
washed twice in cold PBS and resuspended in binding
buffer at a concentration of 1 × 106/ml. The cells were
then exposed to the labeling solutions phycoerythrin con-
jugated-Annexin V and 7-AAD for 15 min. Flow cytometry
analysis was performed using FACSCalibur with CEL-
LQuest software (BD Biosciences, Mountain View, Cali-
fornia, USA). Both early apoptotic (annexin V-positive
and 7-AAD-negative) and late apoptotic (annexin V- neg-
ative and 7 AAD-positive) cells were included in the anal-
ysis.
Plasmid DNA Constructs and Preparations
DNA fragment encoding M. tuberculosis Hsp70 was
obtained from pKS70. For the generation of Hsp70-
expressing plasmid (pcDNA3-hsp70), the hsp70 was sub-
cloned from pKS70 plasmid into the unique BamHI and
HindIII cloning sites of the pcDNA3.1 expression vector
(Invitrogen, Carlsbad, California, USA) downstream of
the cytomegalovirus promoter [18]. The generation of
HPV-16 E7-expressing plasmid (pcDNA3-E7) and the E7-
hsp70 chimera DNA (pcDNA-E7-hsp70) has been
described previously [6].
DNA Vaccination
DNA-coated gold particles were prepared, and gene gun
particle-mediated DNA vaccination was performed,
according to a protocol described previously [6]. Gold
particles coated with DNA vaccines (1 g DNA/bullet)
were delivered to the shaved abdominal regions of mice
by using a helium-driven gene gun (Bio-Rad Laboratories
Inc., Hercules, Calif.) with a discharge pressure of 400 lb/
in2. C57BL/6 mice (5 per group) were immunized with 2
g of the DNA vaccine and received a booster dose 7 days
after the first vaccination.
Intracytoplasmic Cytokine Staining and Flow Cytometry 
Analysis
Pooled splenocytes from mice treated with the various
treatment regiments were harvested either 14 days (for
primary immune response) and 42 days (for memory
immune response) after tumor challenge. For the memory
recall experiment, the vaccinated mice were re-vaccinated
twice with E7-HSP70 DNA vaccine, 60 days after the last
vaccination to generate the memory recall response. Ten
days after the recall vaccination, splenocytes were har-
vested and incubated for 20 h with 1 g/ml of E7 peptide
containing an MHC class I epitope (aa49-57,
RAHYNIVTF) in the presence of GolgiPlug (BD Pharmin-
gen, San Diego, California, USA) [19]. The stimulated
splenocytes were then washed once with FACScan buffer
and stained with phycoerythrin-conjugated monoclonal
rat anti-mouse CD8a (clone 53.6.7). Cells were subjected
to intracellular cytokine staining using the Cytofix/
Cytoperm kit according to the manufacturer's instruction
(BD Pharmingen, San Diego, CA, USA). Intracellular IFN-
 was stained with FITC-conjugated rat anti-mouse IFN-.
All antibodies were purchased from BD Pharmingen.
Flow cytometry analysis was performed using FACSCali-
bur with CELLQuest software (BD Biosciences, Mountain
View, California, USA).
In Vivo Tumor Treatment Experiments
C57BL/6 mice were divided into four groups (control, api-
genin only, E7-hsp70 only, and apigenin with E7-hsp70).
All mice were inoculated with TC-1 cells (5 × 104) s.c. over
right leg. For the control group, mice were regularly fol-
lowed after TC-1 implantation without specific treatment.
For the apigenin only group, 3 days after TC-1 implanta-
tion, each mouse was given i.p. apigenin (25 mg/kg) and
continued for 10 days. For the E7-hsp70 only group, 3
days after TC-1 implantation, each mouse was vaccinated
with E7-hsp70 2 g via gene gun first, and was boosted 7
d later. For the apigenin with E7-hsp70 group, after TC-1
implantation, each mouse received the same vaccination
schedule as the E7-hsp70 only group, and the same i.p.
apigenin schedule as the apigenin only group.Journal of Biomedical Science 2009, 16:49 http://www.jbiomedsci.com/content/16/1/49
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Statistical Analysis
Statistical analysis was performed using Prism 3.0 soft-
ware (GraphPad, San Diego, California, USA). Observed
differences in apoptosis between different concentrations
of apigenin were evaluated using student's t test. Differ-
ences in IFN- expression in CD8+ cells were measured
using Pearson's chi-square test. Survival curves were plot-
ted using Kaplan-Meier method and compared by log-
rank test. For all analyses p < 0.05 was considered statisti-
cally significant. Data are presented as mean ± standard
deviation (SD) unless otherwise specified.
Results
Treatment with apigenin renders the TC-1 tumor cells 
more susceptible to lysis by E7-specific CTLs
In order to determine if treatment of TC-1 tumor cells
with apigenin will render the tumor cell more susceptible
to E7-specific T cell-mediated killing, we performed a
cytotoxicity assay using luciferase-expressing TC-1 tumor
cells. TC-1/luc tumor cells were (i) treated with DMSO as
a control, (ii, iii, iv) treated with different concentrations
of apigenin, (v, vi) treated with E7-specific cytotoxic T
cells at different E:T ratios (1:1, 1:5), or (vii, viii) treated
with apigenin and E7-specific CTLs at different E:T ratios
(1:1, 1:5). The CTL-mediated killing of the TC-1 tumor
cells in each well was monitored using bioluminescent
imaging systems over time. The degree of CTL-mediated
killing of the tumor cells was indicated by the decrease of
luminescence activity. As shown in Figure 1, cells treated
with apigenin demonstrated a dose- and time-dependent
reduction of luciferase activity. Furthermore, a signifi-
cantly lower luciferase activity was observed in the wells
incubated with apigenin and E7-specific CTLs at an E:T
ratio of 1:5 as compared to the wells incubated with api-
genin alone or E7-specific CTLs alone (p < 0.05). Thus,
our data suggests that the TC-1 tumor cells treated with
apigenin increased the susceptibility of the tumor cells for
lysis by the E7-specific cytotoxic T cells.
Treatment of TC-1 tumor cells with apigenin enhances the 
apoptotic tumor cell death in vitro in a dose-dependant 
manner
In order to determine the effect of chemotherapy on TC-1
tumor cells, we incubated TC-1 tumor cells with different
doses of apigenin (20, 40, 80 M). The cells were then
characterized for apoptotic cell death using annexin V and
7-AAD staining. As shown in Figure 2, we observed that
TC-1 tumor cells treated with the higher doses of apigenin
demonstrated a greater degree of apoptotic tumor cell
death compared to control untreated TC-1 tumor cells
both at 6 hours and at 48 hours following incubation with
apigenin. Thus, our data indicate that treatment with api-
genin enhances the apoptotic tumor cell death in TC-1
tumors in a dose dependant manner.
TC-1 tumor-bearing mice treated with apigenin combined 
with E7-HSP70 DNA generate highest frequency of 
primary and memory E7-specific CD8+ T cells
In order to determine the E7-specific CD8+ T cell immune
response in tumor-bearing mice treated with apigenin in
combination with the E7-HSP70 DNA vaccine, we first
challenged groups of C57BL/6 mice (5 per group) with
TC-1 tumor cells and then treated them with apigenin
alone, E7-HSP70 DNA vaccine alone or apigenin in com-
bination with DNA vaccination. Untreated tumor-bearing
mice were used as negative controls. Splenocytes were har-
vested from vaccinated mice 14 days (for primary
immune response) and 42 days (for memory immune
response) after tumor challenge and characterized the
presence of E7-specific CD8+ T cells in treated mice using
intracellular cytokine staining for IFN- followed by flow
cytometry analysis. As shown in Figure 3, tumor-bearing
mice that were treated with apigenin in combination with
E7-HSP70 DNA generated a significantly higher number
of primary as well as memory E7-specific CD8+ T cells
compared to tumor-bearing mice that were administered
E7-HSP70 DNA alone or apigenin alone (p < 0.05). These
results indicate that treatment of tumor-bearing mice with
apigenin in combination with E7-HSP70 DNA leads to
the strongest E7-specific CD8+ T cell immune responses.
TC-1 tumor-bearing mice treated with apigenin combined 
with E7-HSP70 DNA generate a significant memory recall 
response of E7-specific CD8+ T cells
In order to determine the memory recall response of E7-
specific CD8+ T cells in tumor-bearing mice treated with
apigenin in combination with the E7-HSP70 DNA vac-
cine, we first challenged groups of C57BL/6 mice (5 per
group) with TC-1 tumor cells and then treated them with
E7-HSP70 DNA vaccine alone or apigenin in combination
with DNA vaccination. Sixty days after the last vaccina-
tion, the mice were vaccinated twice with E7-HSP70 DNA
vaccine to generate the memory recall response. Ten days
after the recall vaccination, splenocytes were harvested
and characterized for E7-specific CD8+ T cells using intra-
cellular IFN- staining followed by flow cytometry analy-
sis. As shown in Figure 4, tumor-bearing mice that were
treated with apigenin in combination with E7-HSP70
DNA generated a significant memory recall response of
E7-specific CD8+ T cells compared to tumor-bearing mice
that were administered E7-HSP70 DNA alone or apigenin
alone (p < 0.05). These results indicate that treatment of
tumor-bearing mice with apigenin in combination with
E7-HSP70 DNA leads to potent E7-specific CD8+ T cell
memory recall responses.Journal of Biomedical Science 2009, 16:49 http://www.jbiomedsci.com/content/16/1/49
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In vitro cytotoxicity assay Figure 1 (see previous page)
In vitro cytotoxicity assay. Luciferase-expressing TC-1 tumor cells were added to 24-well plates at a dose of 1 × 105/well. 
TC-1/luc tumor cells were (A & B) treated with solvent DMSO (0.1%) as a control or treated with different concentrations of 
apigenin (20, 40, 80 M) or (C & D) treated with E7-specific cytotoxic T cells at different E:T ratios (1:1, 1:5) with or without 
treated 40 mM apigenin. Bioluminescence imaging was performed on D0, D1, D2 and D3. The degree of CTL-mediated killing 
of the tumor cells was indicated by the decrease of luminescence activity using the IVIS luminescence imaging system series 
200. Bioluminescence signals were acquired for 10 seconds. (A & C) Representative luminescence images of 24-well plates 
showing lysis of the tumor cells by (A) different concentrations of apigenin or by (C) E7-specific T cells and apigenin. (B & D) 
Bar graph depicting the quantification of luminescence intensity in tumor cells treated with (B) different concentrations of api-
genin or treated with (D) apigenin and/or E7-specific cytotoxic T cells (mean ± SD). P values less than 0.05 are considered to 
be statistically significant. Data shown are representative of two experiments performed.
Flow cytometry analysis to determine the number of apoptotic cells induced by apigenin treatment Figure 2
Flow cytometry analysis to determine the number of apoptotic cells induced by apigenin treatment. TC-1 cells 
were co-incubated with various concentrations of apigenin (20, 40, 80 M). Cells treated with solvent DMSO (0.1%) alone 
were used as controls. The cells were then stained with PE-conjugated annexin V antibody (BD, San Diego) and 7-AAD to 
detect the expression of annexin V and 7-AAD. Flow cytometry analysis was performed to characterize the expression of 
annexin V+ 7-AAD+ (apoptotic) cells among the TC-1 cells treated with apigenin. A & B. Representative flow cytometry data 
demonstrating the percentage of apoptotic cells at (A) 6 hours after incubation or (B) 48 hours after incubation with different 
concentrations of apigenin. C & D. Bar graphs depicting in the percentage of apoptotic cells at (C) 6 hours after incubation or 
(D) 48 hours after incubation with different concentrations of apigenin. Data shown are representative of two experiments 
performed (mean ± SD).Journal of Biomedical Science 2009, 16:49 http://www.jbiomedsci.com/content/16/1/49
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Intracellular cytokine staining followed by flow cytometry analysis to determine the number of primary and memory E7-specific  CD8+ T cells in tumor-bearing mice treated with apigenin and/or E7-HSP70 DNA vaccine Figure 3
Intracellular cytokine staining followed by flow cytometry analysis to determine the number of primary and 
memory E7-specific CD8+ T cells in tumor-bearing mice treated with apigenin and/or E7-HSP70 DNA vaccine. 
Groups of C57BL/6 mice (5 per group) were challenged subcutaneously with 1 × 104/mouse of TC-1 tumor cells. Mice were 
treated with apigenin alone, E7-HSP70 DNA vaccine alone, the combination of apigenin and the E7-HSP70 DNA vaccine. Api-
genin was administered intraperitoneally at the dose of 25 mg/kg after TC-1 inoculation and continued for 10 days. Mice were 
vaccinated with 2 g/mouse of E7-HSP70 via gene gun, 3 days before TC-1 inoculation and receive a booster dose 7 days after 
the first vaccination. Untreated tumor challenged mice were used as negative controls. 14 days (for primary immune response) 
and 42 days (for memory immune response) after tumor challenge, splenocytes from mice were harvested and stained for 
CD8 and intracellular IFN- and then characterized for E7-specific CD8+ T cells using intracellular IFN- staining followed by 
flow cytometry analysis. A & B. Representative data of intracellular cytokine stain followed by flow cytometry analysis showing 
the number of E7-specific IFN+ CD8+ T cells in mice treated with apigenin and/or DNA vaccine at (A) 14 days or (B) 42 days 
after tumor challenge. C & D. Bar graph depicting the numbers of E7-specific IFN--secreting CD8+ T cells per 3 × 105 pooled 
splenocytes at (C) 14 days or (D) 42 days after tumor challenge. Data shown are representative of two experiments per-
formed (mean ± SD).Journal of Biomedical Science 2009, 16:49 http://www.jbiomedsci.com/content/16/1/49
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TC-1 tumor-bearing mice treated with apigenin combined 
with E7-HSP70 DNA vaccination generate the best 
therapeutic anti-tumor effects
To determine the therapeutic antitumor effects generated
by apigenin combined with E7-HSP70 DNA vaccination,
we first challenged groups of C57BL/6 mice (5 per group)
with TC-1 tumor cells and then treated them with api-
genin alone, E7-HSP70 DNA vaccine alone or apigenin in
combination with DNA vaccination. Untreated tumor-
bearing mice were used as negative controls. As shown in
Figure 5, tumor-bearing mice treated with apigenin in
combination with E7-HSP70 DNA showed significantly
reduced tumor size over time as compared to tumor-bear-
ing mice treated with chemotherapy alone or the DNA
vaccine alone (p = 0.001). Furthermore, tumor-bearing
mice treated with apigenin in combination with E7-
HSP70 DNA showed improved survival compared to
tumor-bearing mice treated with apigenin alone or the
DNA vaccine alone (p = 0.037). (Figure 1C). Thus, our
data indicate that the treatment regimen using apigenin in
combination with E7-HSP70 DNA vaccination produces
the best therapeutic anti-tumor effects and long-term sur-
vival in TC-1 tumor-bearing mice.
Discussion
In the current study, we observed that treatment with api-
genin enhanced apoptotic tumor cell death and rendered
the TC-1 tumor cells more susceptible to lysis by E7-spe-
cific CTLs. TC-1 tumor-bearing mice treated with apigenin
combined with E7-HSP70 DNA were found to generate
significant effector and memory E7-specific CD8+ T cell
immune responses, thus generating strong therapeutic
anti-tumor effects. Thus, treatment with the combination
Intracellular cytokine staining followed by flow cytometry analysis to determine the memory recall response of E7-specific  CD8+ T cells in tumor-bearing mice treated with apigenin and/or E7-HSP70 DNA vaccine Figure 4
Intracellular cytokine staining followed by flow cytometry analysis to determine the memory recall response 
of E7-specific CD8+ T cells in tumor-bearing mice treated with apigenin and/or E7-HSP70 DNA vaccine. Groups 
of C57BL/6 mice (5 per group) were challenged subcutaneously with 1 × 104/mouse of TC-1 tumor cells. Mice were treated 
with apigenin alone, E7-HSP70 DNA vaccine alone, or the combination of apigenin and the E7-HSP70 DNA vaccine as 
described in Figure 3. Untreated tumor challenged mice were used as negative controls. Sixty days after the last vaccination, 
the mice were vaccinated twice with E7-HSP70 DNA vaccine to generate the memory recall response. Ten days after the 
recall vaccination, splenocytes were harvested and stained for CD8 and intracellular IFN- and then characterized for E7-spe-
cific CD8+ T cells using intracellular IFN- staining followed by flow cytometry analysis. (A) Representative data of intracellular 
cytokine stain followed by flow cytometry analysis showing the memory recall response of E7-specific IFN+ CD8+ T cells in 
mice treated with apigenin and/or DNA vaccine. (B) Bar graph depicting the numbers of E7-specific IFN--secreting CD8+ T 
cells per 3 × 105 pooled splenocytes.Journal of Biomedical Science 2009, 16:49 http://www.jbiomedsci.com/content/16/1/49
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of DNA vaccine and apigenin is efficient in generated sig-
nificant antitumor effects against E7-specific tumors.
In our study, we observed that treatment with apigenin
led to an increase in the apoptotic cell death of the TC-1
tumor cells (See Figure 2). Our results are consistent with
previous studies by other investigators. For example, api-
genin has previously been shown to inhibit the growth of
human cervical carcinoma cells by inducing apoptosis
through a p53-dependant pathway by Zheng et al [20].
They also showed that the HeLa cells treated with api-
genin were arrested at G1 phase and demonstrated
increased expression of the pro-apoptotic factors, Fas/
APO-1, caspase-3 and p21/WAF1 protein and decreased
expression of the anti-apoptotic protein, Bcl-2. Thus, the
employment of apigenin may lead to apoptotic cell death
in a variety of tumors.
The increased apoptotic tumor cell death caused by treat-
ment with apigenin may contribute to the observed
enhancement in antigen-specific immune responses gen-
erated by DNA vaccination (See Figure 3). One potential
mechanism for the observed effect is that the apoptotic
tumor cells may be taken up by antigen-presenting cells,
resulting in the activation of tumor-specific CD8+ T cells
(so called cross-priming mechanism). We and others have
previously shown that chemotherapeutic agents that are
capable of causing apoptotic cell death such as EGCG
[21], cisplatin [22] or bortezomib [23] can significantly
enhance the HPV antigen-specific CD8+ T cell immune
responses induced by therapeutic HPV DNA vaccination,
resulting in potent antitumor effects. Therefore, the apop-
totic cell death caused by apigenin may contribute to the
observed enhancement in the DNA vaccine potency.
For clinical translation, it is important to address issues
regarding drug toxicity. Apigenin has been tested in sev-
eral clinical trials and proven to be safe in humans
[24,25]. Furthermore, it is also important to address con-
cerns regarding the potential for oncogenicity associated
with administration of E7 as DNA vaccines into the body.
Thus, the clinical grade GMP grade E7/HSP70 DNA vac-
In vivo tumor treatment experiments Figure 5
In vivo tumor treatment experiments. Groups of C57BL/6 mice (5 per group) were subcutaneously challenged with 5 × 
104/mouse of TC-1 tumor cells. Tumor challenged mice were treated with apigenin and/or E7-HSP70 DNA vaccine as indi-
cated in Figure 3. Untreated TC-1 tumor-bearing mice were used as a control. (A) Line graph depicting the tumor volume in 
TC-1 tumor bearing mice treated with apigenin and/or E7-HSP70 DNA. (B) Kaplan & Meier survival analysis of TC-1 tumor 
challenged mice treated with apigenin and/or E7-HSP70 DNA. Data shown are representative of two experiments performed 
(mean ± SD).Journal of Biomedical Science 2009, 16:49 http://www.jbiomedsci.com/content/16/1/49
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cine that is being used for our clinical studies (pNGVL4a-
Sig/E7(detox)/HSP70) [7] encodes attenuated (detox)
versions of E7 antigen that has a mutation at position 24
and/or 26, which will disrupt the Rb binding site of E7,
abolishing the capacity of E7 to transform cells [26]. Fur-
thermore, we have also used codon optimized E7 DNA in
our vaccine constructs, which has been shown to enhance
the expression of E7 antigen in DCs, leading to increased
translation of the DNA vaccine in DCs [27,28].
In addition, clinical translation may preclude the use of
the pcDNA3 vector, because it contains an ampicillin
resistance gene. Thus, our clinical grade DNA vaccine has
used the pNGVL4a vector obtained from the NIH
National Gene Vector Laboratory for DNA vaccine devel-
opment. This vector is a second-generation plasmid
derived from pNGVL-3, which has been previously used
for human clinical trials [29]. The pNGVL4a vector lacks
the ampicillin resistance gene and thus would be suitable
for clinical translation of the current DNA vaccines.
In summary, our data suggest that vaccination with E7-
HSP70 DNA vaccine in combination with apigenin gener-
ates significantly better E7-specific immune responses as
well as therapeutic antitumor effects. The preclinical
observations serve as an important foundation for future
clinical translation using apigenin in combination with
therapeutic HPV DNA vaccines for the control of HPV-
associated lesions.
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